MeiraGTx posts corporate deck highlighting late-stage gene therapy pipeline, riboswitch platform - MGTX News | RalliesMeiraGTx posts corporate deck highlighting late-stage gene therapy pipeline, riboswitch platform
M
MGTX• Corporate deck highlights late-stage programs and partnership updates
- MeiraGTx highlighted four late-stage gene therapy programs, led by AAV-AQP1 in pivotal Phase 2 for radiation-induced xerostomia.
- BLA filing for AAV-AQP1 targeted for mid 2027, supported by Breakthrough Therapy, RMAT, and orphan drug designations.
- Botaretigene sparoparvovec in X-linked retinitis pigmentosa completed Phase 3; BLA and MAA submissions planned in 2026.
- AAV-GAD in Parkinson’s disease was described as Phase 3 ready; potential BLA filing targeted in 2028.
- Partnership updates included Eli Lilly paying $75 million upfront for AAV-AIPL1, with up to $135 million in near-term milestones.
•
